PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer

Biochemical and Biophysical Research Communications

Volumn 414, Issue 3, 2011, Pages 575-580

  Cho, Hee Jun ^a   Baek, Kyoung Eun ^a   Nam, In Koo ^a   Park, Sun Mi ^a   Kim, In Kyu ^a   Park, Seung Ho ^a   Im, Min Ju ^a   Ryu, Ki Jun ^a   Yoo, Jong Min ^a   Hong, Soon Chan ^b   Kim, Jae Won ^a   Lee, Chang Won ^a   Yoo, Jiyun ^a  

^a Gyeongsang National University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Apoptosis; Cisplatin; Invasion; PLC ; RhoGDI2

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; CISPLATIN; PEPTIDES AND PROTEINS; PHOSPHOLIPASE C GAMMA; RHO GDP DISSOCIATION INHIBITOR 2 PROTEIN; STAUROSPORINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INVASION; CELL INVASION; CELL STRAIN; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; NEOPLASM INVASIVENESS; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 80054897513     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.121     Document Type: Article

References (38)

1. Barocas D.A., Clark P.E. Bladder cancer. Curr. Opin. Oncol. 2008, 20:307-314.
2. Ferraldeschi R., Baka S., Jyoti B., Faivre-Finn C., Thatcher N., Lorigan P. Modern management of small-cell lung cancer. Drugs 2007, 67:2135-2152.
3. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
4. Moehler M., Galle P.R., Gockel I., Junginger T., Schmidberger H. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer. Best Pract. Res. Clin. Gastroenterol. 2007, 21:965-981.
5. Yuan J.N., Chao Y., Lee W.P., Li C.P., Lee R.C., Chang F.Y., Yen S.H., Lee S.D., Whang-Peng J. Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Med. Oncol. 2008, 25:201-206.
6. Andrews P.A., Jones J.A., Varki N.M., Howell S.B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun. 1990, 2:93-100.
7. Dovas A., Couchman J.R. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem. J. 2005, 390:1-9.
8. DerMardirossian C., Bokoch G.M. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 2005, 15:356-363.
9. Hart M.J., Maru Y., Leonard D., Witte O.N., Evans T., Cerione R.A. A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs. Science 1992, 258:812-815.
10. Chuang T.H., Xu X., Knaus U.G., Hart M.J., Bokoch G.M. GDP dissociation inhibitor prevents intrinsic and GTPase activating protein-stimulated GTP hydrolysis by the Rac GTP-binding protein. J. Biol. Chem. 1993, 268:775-778.
11. Scherle P., Behrens T., Staudt L.M. Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc. Natl. Acad. Sci. USA 1993, 90:7568-7572.
12. Yin L., Schwartzberg P., Scharton-Kersten T.M., Staudt L., Lenardo M. Immune responses in mice deficient in Ly-GDI, a lymphoid-specific regulator of Rho GTPases. Mol. Immunol. 1997, 34:484-491.
13. Tapper J., Kettunen E., El-Rifai W., Seppala M., Andersson L.C., Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet. Cytogenet. 2001, 128:1-6.
14. Zhang Y., Zhang B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res. 2006, 66:5592-5598.
15. Cho H.J., Baek K.Y., Park S.M., Kim I.K., Choi Y.L., Cho H.J., Nam I.K., Hwang E.M., Park J.Y., Han J.Y., Kang S.S., Kim D.C., Lee W.S., Lee M.N., Oh G.T., Kim J.W., Lee C.W., Yoo J. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer. Clin. Cancer Res. 2009, 15:2612-2619.
16. Cho H.J., Baek K.Y., Park S.M., Kim I.K., Nam I.K., Choi Y.L., Park S.H., Im M.J., Choi J., Ryu J., Kim J.W., Lee C.W., Kang S.S., Yoo J. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 2011, 311:48-56.
17. Groysman M., Hornstein I., Alcover A., Katzav S. Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducer in T cell antigen receptor-induced pathways. J. Biol. Chem. 2002, 277:50121-50130.
18. Plo I., Lautier D., Casteran N., Dubreuil P., Arock M., Laurent G. Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cgamma. Oncogene 2001, 20:6752-6763.
19. Wang X.T., McCullough K.D., Wang X.J., Carpenter G., Holbrook N.J. Oxidative stress-induced phospholipase C-gamma 1 activation enhances cell survival. J. Biol. Chem. 2001, 276:28364-28371.
20. Bai X.C., Deng F., Liu A.L., Zou Z.P., Wang Y., Ke Z.Y., Ji Q.S., Luo S.Q. Phospholipase C-gamma1 is required for cell survival in oxidative stress by protein kinase C. Biochem. J. 2002, 363:395-401.
21. 2-induced cell death. Kidney Blood Press. Res. 2008, 31:1-9.
22. Smith R.J., Sam L.M., Justen J.M., Bundy G.L., Bala G.A., Bleasdale J.E. Receptor-coupled signal transduction in human polymorphonuclear neutrophils: effects of a novel inhibitor of phospholipase C-dependent processes on cell responsiveness. J. Pharmacol. Exp. Ther. 1990, 253:688-697.
23. Caponigro F., French R.C., Kaye S.B. Protein kinase C: a worthwhile target for anticancer drugs?. Anticancer drugs 1997, 8:26-33.
24. Thomas S.M., Coppelli F.M., Wells A., Gooding W.E., Song J., Kassis J., Drenning S.D., Grandis J.R. Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res. 2003, 63:5629-5635.
25. Shepard C.R., Kassis J., Whaley D.L., Kim H.G., Wells A. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 2007, 26:3020-3026.
26. Sala G., Dituri F., Raimondi C., Previdi S., Maffucci T., Mazzoletti M., Rossi C., Iezzi M., Lattanzio R., Piantelli M., Iacobelli S., Broggini M., Falasca M. Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res. 2008, 68:10187-10196.
27. Nozawa H., Howell G., Suzuki S., Zhang Q., Qi Y., Klein-Seetharaman J., Wells A., Grandis J.R., Thomas S.M. Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin. Cancer Res. 2008, 14:4336-4344.
28. Cho H.J., Baek K.Y., Yoo J. RhoGDI2 as a therapeutic target in cancer. Expert Opin. Ther. Targets 2010, 14:67-75.
29. Ma L., Xu G., Sotnikova A., Szczepanowski M., Giefing M., Krause K., Krams M., Siebert R., Jin J., Klapper W. Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Br. J. Haematol. 2007, 139:217-223.
30. Seraj M.J., Harding M.A., Gildea J.J., Welch D.R., Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin. Exp. Metastasis 2000, 18:519-525.
31. Gildea J.J., Seraj M.J., Oxford G., Harding M.A., Hampton G.M., Moskaluk C.A., Frierson H.F., Conaway M.R., Theodorescu D. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002, 62:6418-6423.
32. Zheng Z., Li J., He X., Chen X., Yu B., Ji J., Zhang J., Wang T., Gu Q., Zhu Z., Liu B. Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil. Hepatogastroenterology 2010, 57:1106-1112.
33. Zhang B., Zhang Y., Dagher M.C., Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res. 2005, 65:6054-6062.
34. Essmann F., Wieder T., Otto A., Muller E.C., Dorken B., Daniel P.T. GDP dissociation inhibitor D4-GDI, but not the homologous RhoGDI1, is cleaved by caspase-3 during drug-induced apoptosis. Biochem. J. 2000, 346:777-783.
35. Sun D., Xu D., Zhang B. Rac signaling in tumorigenesis and as target for anticancer drug development. Drug Resist. Updat. 2006, 9:274-287.
36. Bromberg Y., Shani E., Joseph G., Gorzalczany Y., Sperling O., Pick E. The GDP-bound form of the small G protein Rac1 p21 is a potent activator of the superoxide-forming NADPH oxidase of macrophages. J. Biol. Chem. 1994, 269:7055-7058.
37. Lin Q., Fuji R.N., Yang W., Cerione R.A. RhoGDI is required for Cdc42-mediated cellular transformation. Curr. Biol. 2003, 13:1469-1479.
38. Moissoglu K., McRoberts K.S., Meier J.A., Theodorescu D., Schwartz M.A. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 2009, 69:2838-2844.